Comera Life Sciences Holdings, Inc. () Stock Analysis | Price, Returns, Financials & Key Metrics

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

5.87 k

Shareholding (Dec 2023)

FII

7.01%

Held by 6 FIIs

DII

92.62%

Held by 2 DIIs

Promoter

0.00%

How big is Comera Life Sciences Holdings, Inc.?

22-Jun-2025

As of Jun 16, Comera Life Sciences Holdings, Inc. has a market capitalization of 0.01, classifying it as a Micro Cap, with net sales of 1.01 million and a net profit loss of 9.03 million over the last four quarters. The company's shareholder's funds were -1.73 million, and total assets were 3.73 million as of Dec 22.

Is Comera Life Sciences Holdings, Inc. overvalued or undervalued?

25-Jun-2025

As of August 10, 2023, Comera Life Sciences Holdings, Inc. is considered risky and overvalued, with a P/E ratio of -0.0007 and poor performance, returning -99.2% over the past year compared to the S&P 500's 10.26%.

Is Comera Life Sciences Holdings, Inc. technically bullish or bearish?

20-Sep-2025

As of June 12, 2025, Comera Life Sciences Holdings, Inc. shows a neutral technical trend with mixed indicators, transitioning from mildly bearish to sideways, while significantly underperforming the S&P 500 with a return of -99.25%.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 0 Million (Micro Cap)

P/E

Industry P/E

Dividend Yield

0.00%

Debt Equity

-1.21

Return on Equity

-920.20%

Price to Book

0.01

Revenue and Profits:

Net Sales:

0 Million

(Quarterly Results - Sep 2023)

Net Profit:

-2 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-50.0%

6 Months

-50.0%

1 Year

0.0%

2 Years

-99.88%

3 Years

-99.99%

4 Years

-100.0%

5 Years

0.0%

Comera Life Sciences Holdings, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

Is Comera Life Sciences Holdings, Inc. technically bullish or bearish?

As of 12 June 2025, the technical trend for Comera Life Sciences Holdings, Inc. has changed from mildly bearish to sideways. The current technical stance is neutral, with a mix of indicators showing mild bullishness on the weekly and monthly MACD and KST, while the daily moving averages indicate a mildly bearish trend. The monthly RSI is bullish, but the weekly RSI shows no trend. Additionally, both Bollinger Bands and Dow Theory indicate a sideways trend with no clear direction. Over the past year, the stock has significantly underperformed the S&P 500, with a return of -99.25% compared to the index's 17.14%....

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

7.10%

EBIT Growth (5y)

-256.77%

EBIT to Interest (avg)

-6.19

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.21

Sales to Capital Employed (avg)

-0.12

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

43.36%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

0.01

EV to EBIT

0.13

EV to EBITDA

0.13

EV to Capital Employed

1.09

EV to Sales

-1.20

PEG Ratio

Dividend Yield

ROCE (Latest)

831.13%

ROE (Latest)

-920.20%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

RSI

Bullish

Bollinger Bands

Sideways

Moving Averages

Mildly Bearish (Daily)

KST

Mildly Bullish

Dow Theory

No Trend

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Dec 2023

Shareholding Compare (%holding)

Majority shareholders

Foreign Institutions

Domestic Funds

Held in 2 Schemes (0.37%)

Foreign Institutions

Held by 6 Foreign Institutions (7.01%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Sep'23 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Sep 2023 is -66.67% vs -25.00% in Jun 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Sep 2023 is -57.14% vs 44.00% in Jun 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Sep'23",
        "Jun'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.10",
          "val2": "0.30",
          "chgp": "-66.67%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-2.10",
          "val2": "-1.50",
          "chgp": "-40.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.10",
          "chgp": "-100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-2.20",
          "val2": "-1.40",
          "chgp": "-57.14%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-15,824.70%",
          "val2": "-4,698.30%",
          "chgp": "-1,112.64%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'22",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2022 is 100.00% vs 0.00% in Dec 2021",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2022 is -227.27% vs -66.67% in Dec 2021",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'22",
        "Dec'21",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.60",
          "val2": "0.30",
          "chgp": "100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-10.40",
          "val2": "-5.40",
          "chgp": "-92.59%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-7.10",
          "val2": "0.10",
          "chgp": "-7,200.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-18.00",
          "val2": "-5.50",
          "chgp": "-227.27%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-16,537.60%",
          "val2": "-17,307.90%",
          "chgp": "77.03%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Sep'23 - QoQ

Sep'23

Jun'23

Change(%)

Net Sales

0.10

0.30

-66.67%

Operating Profit (PBDIT) excl Other Income

-2.10

-1.50

-40.00%

Interest

0.00

Exceptional Items

0.00

0.10

-100.00%

Consolidate Net Profit

-2.20

-1.40

-57.14%

Operating Profit Margin (Excl OI)

-15,824.70%

-4,698.30%

-1,112.64%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Sep 2023 is -66.67% vs -25.00% in Jun 2023

Consolidated Net Profit

QoQ Growth in quarter ended Sep 2023 is -57.14% vs 44.00% in Jun 2023

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'22

Dec'22

Dec'21

Change(%)

Net Sales

0.60

0.30

100.00%

Operating Profit (PBDIT) excl Other Income

-10.40

-5.40

-92.59%

Interest

0.00

Exceptional Items

-7.10

0.10

-7,200.00%

Consolidate Net Profit

-18.00

-5.50

-227.27%

Operating Profit Margin (Excl OI)

-16,537.60%

-17,307.90%

77.03%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2022 is 100.00% vs 0.00% in Dec 2021

Consolidated Net Profit

YoY Growth in year ended Dec 2022 is -227.27% vs -66.67% in Dec 2021

All Annual Results

Company CV

About Comera Life Sciences Holdings, Inc.

Comera Life Sciences Holdings, Inc.

Pharmaceuticals & Biotechnology

No Details Available.

Company Coordinates

No Company Details Available

Comera Life Sciences Holdings, Inc.

1Day

52 Week

CASH

FII

DII

Promoter

How big is Comera Life Sciences Holdings, Inc.?

Watch in Real-Time

Is Comera Life Sciences Holdings, Inc. overvalued or undervalued?

Is Comera Life Sciences Holdings, Inc. technically bullish or bearish?

MarketsMojo — Loved in India, Now Global

Dashboard

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

Is Comera Life Sciences Holdings, Inc. technically bullish or bearish?

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot : Dec 2023

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Sep'23 - QoQ

Annual Results Snapshot (Consolidated) - Dec'22

About Comera Life Sciences Holdings, Inc.

Company Coordinates